

SmartPA Criteria Proposal

Drug/Drug Class:	Beta Adrenergic Agents, Long Acting PDL Edit
First Implementation Date:	November 10, 2004
Proposed Date:	April 18, 2023
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Long-acting beta-agonists open the airways by relaxing smooth muscle around the airways. They do not decrease inflammation of pulmonary tissues and are often used with inhaled steroids as a long-term control medication to open the airways in people with moderate to severe asthma.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Serevent® Diskus 	<ul style="list-style-type: none"> Arformoterol Brovana® Formoterol Perforomist® Striverdi® Respimat®

Type of Criteria: ☐ Increased risk of ADE
☐ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Beta Adrenergic Agents, Long Acting
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- For non-preferred agents:
 - Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
 - Documented trial period of preferred agent **OR**
 - Documented ADE/ADR to preferred agent **AND**
 - For Formoterol: documented therapeutic trial of Arformoterol**

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Lack of adequate trial on required preferred agent

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: RESPIRATORY: Beta-Adrenergic Agents, Long Acting", Gainwell Technologies; Last updated January 24, 2023.
- Evidence-Based Medicine Analysis: "Long-Acting Beta-2 Adrenergic Agonist Agents", UMKC-DIC; Last updated October 2022.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.